Cannara Biotech Statistics

Total Valuation

Cannara Biotech has a market cap or net worth of CAD 67.51 million. The enterprise value is 109.22 million.

Market Cap	67.51M
Enterprise Value	109.22M

Important Dates

The last earnings date was Friday, November 29, 2024.

Earnings Date	Nov 29, 2024
Ex-Dividend Date	n/a

Share Statistics

Cannara Biotech has 90.02 million shares outstanding. The number of shares has increased by 1.83% in one year.

Current Share Class	n/a
Shares Outstanding	90.02M
Shares Change (YoY)	+1.83%
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	2.10%
Owned by Institutions (%)	n/a
Float	43.90M

Valuation Ratios

The trailing PE ratio is 10.71.

PE Ratio	10.71
Forward PE	n/a
PS Ratio	0.83
PB Ratio	0.77
P/TBV Ratio	0.77
P/FCF Ratio	21.01
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.80, with an EV/FCF ratio of 33.98.

EV / Earnings	16.96
EV / Sales	1.34
EV / EBITDA	7.80
EV / EBIT	14.29
EV / FCF	33.98

Financial Position

The company has a current ratio of 2.50, with a Debt / Equity ratio of 0.55.

Current Ratio	2.50
Quick Ratio	0.73
Debt / Equity	0.55
Debt / EBITDA	3.45
Debt / FCF	15.04
Interest Coverage	1.51

Financial Efficiency

Return on equity (ROE) is 7.68% and return on invested capital (ROIC) is 3.65%.

Return on Equity (ROE)	7.68%
Return on Assets (ROA)	3.22%
Return on Capital (ROIC)	3.65%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.55
Inventory Turnover	1.41

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -16.67% in the last 52 weeks. The beta is 1.08, so Cannara Biotech's price volatility has been similar to the market average.

Beta (5Y)	1.08
52-Week Price Change	-16.67%
50-Day Moving Average	0.69
200-Day Moving Average	0.73
Relative Strength Index (RSI)	52.68
Average Volume (20 Days)	26,414

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cannara Biotech had revenue of CAD 81.75 million and earned 6.44 million in profits. Earnings per share was 0.07.

Revenue	81.75M
Gross Profit	29.79M
Operating Income	7.64M
Pretax Income	4.48M
Net Income	6.44M
EBITDA	13.74M
EBIT	7.64M
Earnings Per Share (EPS)	0.07

Full Income Statement

Balance Sheet

The company has 6.62 million in cash and 48.33 million in debt, giving a net cash position of -41.71 million or -0.46 per share.

Cash & Cash Equivalents	6.62M
Total Debt	48.33M
Net Cash	-41.71M
Net Cash Per Share	-0.46
Equity (Book Value)	87.95M
Book Value Per Share	0.98
Working Capital	40.47M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 10.68 million and capital expenditures -7.47 million, giving a free cash flow of 3.21 million.

Operating Cash Flow	10.68M
Capital Expenditures	-7.47M
Free Cash Flow	3.21M
FCF Per Share	0.04

Full Cash Flow Statement

Margins

Gross margin is 36.44%, with operating and profit margins of 9.35% and 7.88%.

Gross Margin	36.44%
Operating Margin	9.35%
Pretax Margin	5.49%
Profit Margin	7.88%
EBITDA Margin	16.81%
EBIT Margin	9.35%
FCF Margin	3.93%

Dividends & Yields

Cannara Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.83%
Shareholder Yield	-1.83%
Earnings Yield	9.33%
FCF Yield	4.76%

Stock Splits

The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.

Last Split Date	Feb 13, 2023
Split Type	Reverse
Split Ratio	0.1

Scores

Cannara Biotech has an Altman Z-Score of 1.57. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.57
Piotroski F-Score	n/a